obesity/nausea

1. FIELD OF THE INVENTION The present invention provides methods of administering an insulinotropic peptide in an amount effective to treat a disorder or condition while reducing nausea. Exemplary disorders or conditions treatable with an insulinotropic peptide include obesity and type II

BACKGROUND OF THE INVENTION Gastrointestinal stimulation, or pacing, was advocated as a possible treatment for gastric motor dysfunction as early as 1963. Experimentation in the late 1960s and early 1970s, began to demonstrate the significance of gastrointestinal myoelectrical activity and its

TECHNICAL FIELD The present invention relates generally to a method of modulating substance P by compounds containing calcium sulfate, particularly syngenite, gorgeyite and gypsum, and more specifically, to the synthesis of such compounds as well as their use to treat a variety of conditions

SUMMARY OF THE INVENTION The present invention is concerned with deuterium-enriched pyridinone carboxamides and derivatives thereof of formula I, ##STR00002## Wherein, R.sub.1 and R.sub.2 are independently, H, D (deuterium with enrichment of 1%-100%), F, Cl, CD.sub.3 (methyl-d.sub.3),

SUMMARY OF THE INVENTION The present invention is concerned with deuterium-enriched pyridinonecarboxamides and derivatives thereof of formula 1, ##STR00002## Wherein, R.sub.1 and R.sub.2 are independently, H, D (deuterium with enrichment of 1%-100%), F, Cl, CD.sub.3 (methyl-d.sub.3),

FIELD OF THE INVENTION The present invention relates to sulfonamide derivatives, to the process for preparing them and to their therapeutic use. BACKGROUND OF THE INVENTION Orexins A and B (or hypocretins 1 and 2) are hypothalamus neuropeptides of 33 and 28 amino acids, respectively, recently

FIELD OF THE INVENTION The present invention relates to compounds and their uses, and in particular to compounds and their therapeutic use in the treatment or prevention of conditions having an association with substrates, such as the neurotransmitter anandamide, which are broken down by the fatty

FIELD OF THE INVENTION The present invention relates to compounds and their uses, and in particular to compounds and their therapeutic use in the treatment or prevention of conditions having an association with substrates, such as the neurotransmitter anandamide, which are broken down by the fatty